Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3

Bioorganic and Medicinal Chemistry

Volumn 19, Issue 15, 2011, Pages 4652-4668

  Maltais, René ^a   Fournier, Michelle Audrey ^a   Poirier, Donald ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Androgen; Androsterone; Cancer; Enzyme; Hormone; Hydroxysteroid dehydrogenase; Steroid

Indexed keywords

(3ALPHA,5ALPHA) 3 (1,4' BIPIPERIDIN 1' YLMETHYL) 3 HYDROXYANDROSTAN 17 ONE; (3ALPHA,5ALPHA) 3 [(4 BENZYLPIPERAZIN 1 YL)METHYL] 3 HYDROXYANDROSTAN 17 ONE; (3ALPHA,5ALPHA) 3 [(4 BENZYLPIPERIDIN 1 YL)METHYL] 3 HYDROXYANDROSTAN 17 ONE; (3ALPHA,5ALPHA) 3 [(DIBUTYLAMINO)METHYL] 3 HYDROXYANDROSTAN 17 ONE; (3ALPHA,5ALPHA) 3 [(DIETHYLAMINO)METHYL] 3 HYDROXYANDROSTAN 17 ONE; (3ALPHA,5ALPHA) 3 [[4 (3 CHLOROBENZYL)PIPERAZIN 1 YL]METHYL] 3 HYDROXYANDROSTAN 17 ONE; (3ALPHA,5ALPHA) 3 [[4 [2,4 BIS(TRIFLUOROMETHYL)BENZYL]PIPERAZIN 1 YL]METHYL] 3 HYDROXYANDROSTAN 17 ONE; (3ALPHA,5ALPHA) 3 [[4 [3,5 BIS(TRIFLUOROMETHYL)BENZYL]PIPERAZIN 1 YL]METHYL] 3 HYDROXYANDROSTAN 17 ONE; (3ALPHA,5ALPHA) 3 [[BENZYL(ETHYL)AMINO]METHYL] 3 HYDROXYANDROSTAN 17 ONE; (3ALPHA,5ALPHA) 3 [[BENZYL(METHYL)AMINO]METHYL] 3 HYDROXYANDROSTAN 17 ONE; (3ALPHA,5ALPHA) 3 [[TRANS 2,5 DIMETHYL 4 [3 (TRIFLUOROMETHYL)BENZYL]PIPERAZIN 1 YL]METHYL] 3 HYDROXYANDROSTAN 17 ONE; (3ALPHA,5ALPHA) 3 HYDROXY 3 (PIPERAZIN 1 YLMETHYL)ANDROSTAN 17 ONE; (3ALPHA,5ALPHA) 3 HYDROXY 3 (PIPERIDIN 1 YLMETHYL)ANDROSTAN 17 ONE; (3ALPHA,5ALPHA) 3 HYDROXY 3 [(4 METHYLPIPERAZIN 1 YL)METHYL]ANDROSTAN 17 ONE; (3ALPHA,5ALPHA) 3 HYDROXY 3 [[2,5 DIMETHYLPIPERAZIN 1 YL]METHYL] 3 HYDROXYANDROSTAN 17 ONE; (3ALPHA,5ALPHA) 3 HYDROXY 3 [[4 (3 METHOXYBENZYL)PIPERAZIN 1 YL]METHYL]ANDROSTAN 17 ONE; (3ALPHA,5ALPHA) 3 HYDROXY 3 [[4 (PYRIDIN 3 YLMETHYL)PIPERAZIN 1 YL]METHYL]ANDROSTAN 17 ONE; (3ALPHA,5ALPHA) 3 HYDROXY 3 [[4 [2 (TRIFLUOROMETHYL)BENZYL]PIPERAZIN 1 YL]METHYL]ANDROSTAN 17 ONE; (3ALPHA,5ALPHA) 3 HYDROXY 3 [[4 [3 (TRIFLUOROMETHYL)BENZYL]PIPERAZIN 1 YL]METHYL]ANDROSTAN 17 ONE; (3ALPHA,5ALPHA) 3 HYDROXY 3 [[4 [3 [(TRIFLUOROMETHYL)SULFANYL]BENZYL]PIPERAZIN 1 YL]METHYL]ANDROSTAN 17 ONE; (3ALPHA,5ALPHA) 3 HYDROXY 3 [[4 [4 (TRIFLUOROMETHYL)BENZYL]PIPERAZIN 1 YL]METHYL]ANDROSTAN 17 ONE; 3 BETA SUBSTITUTED 3 ALPHA HYDROXY ANDROSTAN 17 ONE DERIVATIVE; 3 SUBSTITUTED ANDROSTERONE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBAMIC ACID DERIVATIVE; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE 3; UNCLASSIFIED DRUG;

ANDROGEN SYNTHESIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HYDROPHOBICITY; PROSTATE CANCER; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION;

17-HYDROXYSTEROID DEHYDROGENASES; ANDROSTERONE; ENZYME INHIBITORS; HEK293 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; PROSTATIC NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

RODENTIA;

EID: 79960564976     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2011.06.003     Document Type: Article

References (35)

1. http://www.cancer.org/Cancer-ProstateCancer/DetailedGuide/ prostate-cancer-key-statistics.
2. Group. VACUR. Surg. Gynecol. Obset. 124 1967 1011
3. J. Seidenfeld, D.J. Samson, V. Hasselblad, N. Aronson, P.C. Albertsen, C.L. Bennett, and T.J. Wilt Ann. Intern. Med. 132 2000 566
4. R.J. Santen J. Clin. Endo. Metab. 75 1992 685
5. P.O. Hedlund Prostate Suppl. 10 2000 32
6. D.K. Wysowski, J.P. Freiman, J.B. Tourtelot, and M.L. Hroton Ann. Intern. Med. 118 1993 860
7. V.B. Shahinian, Y.F. Kuo, J.L. Freeman, and J.S. Goodwin N. Eng. J. Med. 352 2005 154
8. T. Tammela J. Steroid Biochem. Mol. Biol. 92 2004 287
9. Y. Laplante, and D. Poirier Steroids 73 2008 266
10. H. Inano, and B.I. Tamaoki Steroids 48 1986 1
11. V. Luu-The, Y. Zhang, D. Poirier, and F. Labrie J. Steroid Biochem. Mol. Biol. 55 1995 581
12. T. Penning Endocr. Relat. Cancer 3 1996 41
13. G. Moeller, and J. Adamski Mol. Cell. Endocrinol. 301 2009 7
14. M.L. Mohler, R. Narayanan, Y. He, D.D. Miller, and J.T. Dalton Recent Pat. Endocr. Metab. Immune Drug Discov. 1 2007 103
15. J.M. Day, H.J. Tutill, A. Purohit, and M.J. Reed Endocr. Relat. Cancer 15 2008 665
16. F. Labrie Mol. Cell. Endocrinol. 78 1991 C113
17. D. Poirier Drug Dev. Res. 69 2008 304
18. V. Luu-The, A. Belanger, and F. Labrie Best Pract. Res. Clin. Endocrinol. Metab. 22 2008 207
19. E. Koh, T. Noda, J. Kanya, and M. Namiki Prostate 53 2002 154
20. V.G. Deqtyar, T.V. Babkina, I.A. Kazantseva, A.P. Morozov, M.F. Trapeznikova, and N.E. Kushlinski Bull. Exp. Biol. Med. 139 2005 715
21. R.B. Montgomery, E.A. Mostaghel, R. Vessella, D. Hess, T.F. Kalhorn, C.S. Higano, L.D. True, and P.S. Nelson Cancer Res. 68 2008 4447
22. J.A. Locke, E. Guns, A.A. Lubik, H.H. Adomat, S.C. Hendy, C.A. Wood, S.L. Ettinger, M.E. Gleave, and C.C. Nelson Cancer Res. 68 2008 6407
23. E.A. Mostaghel, S.T. Page, D.W. Lin, L. Fazli, I.M. Coleman, L.D. True, B. Knudsen, D.L. Hess, C.C. Nelson, A.M. Matsumoto, W.J. Bremner, M.E. Gleave, and P. Nelson Cancer Res. 67 2007 5033
24. S.T. Page, D.W. Lin, E.A. Mostaghel, D.L. Hess, L.D. True, J.K. Amory, P.S. Nelson, A.M. Matsumoto, and W.J. Bremner J. Clin. Endocrinol. Metab. 91 2006 3850
25. L.G. Wang, S.K. Mencher, J.P. McCarron, and A.C. Ferrari Oncol. Rep. 11 2004 1325
26. R.L. Leibowitz, and S.J. Tucker Oncologist 6 2001 177
27. R. Maltais, V. Luu-The, and D. Poirier J. Med. Chem. 45 2002 640
28. B. Tchedam-Ngatcha, Y. Laplante, F. Labrie, V. Luu-The, and D. Poirier Mol. Cell. Endocrinol. 248 2006 225
29. B. Tchedam-Ngatcha, V. Luu-The, F. Labrie, and D. Poirier J. Med. Chem. 48 2005 5257
30. R. Maltais, and D. Poirier Tetrahedron Lett. 39 1998 4151
31. R. Maltais, V. Luu-The, and D. Poirier Bioorg. Med. Chem. 9 2001 3101
32. M. Berube, Y. Laplante, and D. Poirier Med. Chem. 2 2006 329
33. M. Berube, and D. Poirier J. Enzyme Inhib. Med. Chem. 22 2007 201
34. http://en.wikipedia.org/wiki/Piperazine.
35. J. Roy, R. Breton, C. Martel, F. Labrie, and D. Poirier Bioorg. Med. Chem. 15 2007 3003